![](https://investorshub.advfn.com/uicon/430424.png?cb=1554906782)
Friday, September 11, 2015 4:29:11 PM
Perhaps your answer already acknowledges the point/question I am submitting, but let me explain it. Pyrr and AVII are diehards about stating that in the past, enrollment must be completed on PFS prior to the first interim analysis. Meaning, for instance, if 348 enrollment had not been met, they would have to wait beyond 149 events to conduct the first interim analysis.
While FDA policies often change, NWBO would not take chances and vary from tradition, unless the resizing negotiations with regulators also agreed to 2 separate enrollments.
Even though the confirmatory trial in DCVax-L's case is likely to be the same phase III trial (plus some satellite data assistance from trials out there conducted by UCLA, IMHO), think of the confirmatory trial as a separate trial, even though it is not.
I think a researcher named Fleming once quoted someone who stated, who is unlucky enough to enter a placebo confirmatory trial after the treatment is initially approved through AA?
The point is, FDASIA and others continue to try and perfect the transition from AA to full approval. One requirement is that the new/confirmatory trial already started before AA is granted on the surrogate trial. Companies and regulators over time learned that one trial could be used for both surrogate and confirmatory proof. (In some cases, the confirmatory trial can conclude single arm, but even better, enrolled while both portions of the trial were still blinded.)
My recollection is that, because of this, the surrogate endpoint is often overpowered. We know we have strong powering for the primary endpoint. So that fits, but to create a more level powering playing field between surrogate and confirmatory portions of the trial, perhaps the surrogate portion of the trial reached full enrollment at 300.
Anyway, if that were the case, then we already reached full enrollment in the surrogate/AA portion of the trial.
(Of course, if this is the case, it means we already had first interim success.)
Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM